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Studies in metabolism and cancer have characterized changes in core pathways involving
glucose and glutamine, emphasizing the provision of substrates for building cell mass. But
recent findings suggest that pathways previously considered peripheral may play a critical
role providing mechanisms for cell regulation. Several of these mechanisms involve the
metabolism of non-essential amino acids, for example, the channeling of glycolytic inter-
mediates into the serine pathway for one-carbon transfers. Historically, we proposed that
the proline biosynthetic pathway participated in a metabolic interlock with glucose metabo-
lism.The discovery that proline degradation is activated by p53 directed our attention to the
initiation of apoptosis by proline oxidase/dehydrogenase. Now, however, we find that the
biosynthetic mechanisms and the metabolic interlock may depend on the pathway from
glutamine to proline, and it is markedly activated by the oncogene MYC.These findings add
a new dimension to the proline regulatory axis in cancer and present attractive potential
targets for cancer treatment.
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INTRODUCTION
The characterization of metabolic reprogramming in tumor cells
has recently progressed rapidly from that first described by Otto
Warburg (Vander Heiden et al., 2009). However, the focus remains
on core metabolism involving glucose and glutamine (Dang and
Semenza, 1999; DeBerardinis et al., 2008; Cairns et al., 2011). The
original speculation of a primary defect in mitochondria has not
been substantiated, but adaptive changes are prominent in mito-
chondrial metabolism (Wallace, 2005). The array of changes in
reprogramming seems at times disparate and even paradoxical,
but they can be understood in a temporo-spatial context (Dang,
2009).
An important consideration is the tumor’s selection of mecha-
nisms to survive hypoxic and nutrient stress, leaving a genetic trail.
HIF and AMPK are critical for survival and are frequently elevated
in tumors, whereas suppressor mechanisms such as p53 are lost
during tumor progression. When the tumor shifts into the pro-
liferative phase and becomes clinically important, it has acquired
reprogramming for rapid growth. Oncogenes such as PI3K/AKT,
PTEN, RAS, and MYC play an important role during this phase
(Vander Heiden et al., 2009; Cairns et al., 2011).
To understand oncometabolism, one must consider the tumor’s
requirement for building blocks to incorporate into cell mass (Van-
der Heiden et al., 2012), i.e., nucleotides for DNA and RNA, amino
acids for protein synthesis and fatty acids for lipid and membrane
synthesis. That glucose is diverted into these biosynthetic pathways
was an important realization, and, indeed, the markedly increased
glucose uptake into tumors can be easily seen on PET scans with
fluorodeoxyglucose – a feature of tumors not only useful for clin-
ically visualizing and localizing tumors (Visioni and Kim, 2011),
but also a hallmark of metabolic reprogramming. The routing of
glucose to lactate and its excretion from the cell was seen as a
mechanism for regenerating NAD+, a co-factor necessary for the
glycolytic pathway at the step of glyceraldehyde-3-P dehydroge-
nase (Locasale and Cantley, 2011). Thus, the maintenance of flux
through the glycolytic pathway requires the sacrifice of pyruvate
to regenerate NAD+.
Glutamine was also recognized as playing a critical role in
tumor metabolism (Wise et al., 2008; Dang, 2009). Physiologically,
this amino acid serves as a conduit for transfer of carbon skeletons
and amino groups from one tissue to another. In the postabsorp-
tive state, proteolysis occurs in muscle, and amino groups from
released amino acids are transferred to glutamate forming gluta-
mine which circulates to the liver and kidney (Roth, 2008). Also
important, the gamma nitrogen of glutamine is used in the initial
steps of de novo purine and pyrimidine biosynthesis (Boza et al.,
2000). Glutamine is sequentially converted to glutamate and alpha
KG which plays an anaplerotic role in the tricarboxylic acid (TCA)
cycle as citrate and malate (Le et al., 2012). Glutamine is not the
only amino acid which has attracted recent attention in the field
of metabolic programming in cancer. In fact, glutamine, arginine,
and proline are a metabolic system. This review emphasizes the
metabolism of proline which plays a special role in ROS signaling
and redox balance (Phang et al., 2008a). Further, recent studies
show that the regulation of glutamine and proline metabolism is
linked in tumor cells.
The emphasis on “core pathways” during the last 10 years has
provided seminal insights (Slaughter and Davies, 1968; Dang,
2009; Locasale and Cantley, 2010; Cairns et al., 2011; Vander Hei-
den et al., 2012). However, it became clear that core pathways were
not the whole story; more “out of the box” thinking was needed.
Additionally, these core pathways did not offer useful targets for
cancer therapy because pharmacologic blockade often produced
severe side effects (Kaufmann et al., 2006; Chang et al., 2007;
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Brandsma et al., 2010; Kaelin and Thompson, 2012). Thus, we
sought evidence for non-core metabolic reprogramming in tumor
cells, and fortuitously, insights have derived from several heuris-
tic models. Tumor arrays, metabolomics, screening for targets
of oncogenes/suppressor genes, and functional tumor suppres-
sion models all have been rewarding. Metabolomics have shown
changes in serine and arginine/proline metabolism (Catchpole
et al., 2009); p53 target screening has shown that POX/PRODH is
a p53-induced gene (Polyak et al., 1997), and that the pyrroline-5-
carboxylate (P5C) synthase gene (Aldh 18a1) is a target of MYC in a
T-cell activation model (Wang et al., 2011b). Most impressive is the
recent systematic screening of anti-tumor effects resulting from
knockdown of metabolic genes by their respective siRNAs (Posse-
mato et al., 2011). This study identified five genes when knocked
down resulted in robust inhibitory effects on tumors. The authors
earmarked 3-phosphoglycerate dehydrogenase (PHGDH), which
channels carbons from glycolysis into the serine biosynthetic path-
way, as an important enzyme by their criteria and targeted it for a
variety of additional studies. Of special interest to us, these authors
also identified PYCR1, pyrroline-5-carboxylate reductase 1, the
enzyme catalyzing the committed step for proline synthesis, which
when knocked down yielded tumor inhibitory effects (Possemato
et al., 2011). It was exciting to discover that proline metabolism
may play a role not only in suppressing tumors which has been our
focus during the last decade, but also in augmenting tumor growth
which may make it a possible therapeutic target. But for the latter,
there was no convincing evidence that proline biosynthesis was
necessary for either bioenergetics or for its direct contributions
to supplying building blocks for cell mass. Thus, we felt the need
to propose a new regulatory model that explained the observed
effects.
PARAMETABOLIC REGULATION
There are examples of metabolic function for which the term
“Parametabolic” might be appropriate. This central idea is that
the importance of apparent core products of a given pathway and
that of co-factors are switched. The so-called metabolic co-factors
are, in fact, the essential products of the metabolic process, and
it is this parametabolic regulation which may be critical in the
reprogramming of cancer cells (see Figure 1). The conversion of
pyruvate to lactate is an example of redox regulation to optimize
the flux of glucose through glycolysis (Locasale and Cantley, 2010).
Certainly, lactate, itself, is not a physiologically important prod-
uct. Instead, it is the generation of NAD+ as a co-factor which
is the critical metabolic endpoint. Although the role of lactate
production has been emphasized for some time, a number of
novel parametabolic pathways are beginning to be appreciated.
A recently discovered example is the routing of glycolytic inter-
mediates into serine (Locasale et al., 2011; Possemato et al., 2011)
not for their contribution to the proteinogenic amino acid pool,
no change in serine or glycine concentration was found; more
likely, this routing occurred because of the important role of the
pathway in 1-carbon transfers which are critical for nucleotide
synthesis and for DNA methylation. The role of hexosamines to
signal the use of glutamine is another recently discovered exam-
ple of parametabolic regulation (Wellen et al., 2010). However,
the best understood example of parametabolic regulation is that
FIGURE 1 | Schematic of proposed parametabolic regulation.The A-B
pathway is in a metabolic interlock with the S-M pathway. Genetic or
epigenetic upregulation of the A-B pathway would result in an increased
production of P. The designated symbols are generic. However, in the
context of the proline regulatory axis, A-B would represent the glutamine to
proline pathway, I1, and I2 would be pyridine nucleotides, the S-M pathway
would represent the oxidative arm of the pentose phosphate pathway and
P would be PP-ribose-P. “Exit” may be either excretion, incorporation into
protein, or another mechanism for departure from the parametabolic
regulatory system.
of redox balance to optimize metabolic pathways (Locasale and
Cantley, 2011).
REDOX REGULATION
As mentioned above, regulation for redox balance plays an impor-
tant parametabolic role in cancer metabolism. The conversion
of pyruvate to lactate and the excretion of lactate from the cell
is well-recognized as a mechanism for regenerating the NAD+
necessary for maintaining the flux catalyzed by glyceraldehyde-
3-phosphate dehydrogenase. This redox regeneration has been
emphasized by a number of investigators (Vander Heiden et al.,
2009; Cairns et al., 2011; Locasale and Cantley, 2011). However,
it was also recognized that the diversion of pyruvate to lactate to
regenerate NAD+ robbed the metabolic system of an essential pre-
cursor for acetyl CoA used for replenishing the TCA cycle as well
as serving as a precursor for fatty acid synthesis. Another possible
downstream role for the generated NAD+ was demonstrated by
the observation that 3-phosphoglycerate is routed into the serine
synthetic pathway (Locasale et al., 2011; Possemato et al., 2011).
Critically, the step catalyzed by 3-phosphoglycerate dehydroge-
nase (PHGDH) requires NAD+ (Slaughter and Davies, 1968).
Furthermore, providing redox regulation at the oxidative arm of
the pentose phosphate pathway (PPP) supplies the PP-ribose-P
for nucleotide synthesis (Tian et al., 1998), even though in certain
tumors and depending on context, the non-oxidative arm may be
important (Tong et al., 2009). The activation of T-cells was accom-
panied by marked increase in flux through the oxidative arm of
the PPP (Wang et al., 2011b), arguing that the contributions of the
oxidative versus non-oxidative arm to ribose-5-phosphate may
depend on redox balance. Thus, not only must the NAD+/NADH
balance be considered, the NADP+/NADPH ratio also may be
important. In the 1970s, Eggleston and Krebs emphasized that
NADP+/NADPH ratios are the rate-limiting co-factor for the for-
mation of ribose-5-phosphate (Veech et al., 1969). But NADPH
has been emphasized in its role for maintenance of the glutathione
system used as defense against oxidizing insult, and p53 regulates
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the PPP to support NADPH formation (Gottlieb and Vousden,
2010). It is significant that MYC activation decreases the defense
mechanism against oxidizing insult (Tuttle et al., 1996), a finding
consistent with the shift of NADP+/NADPH during prolifera-
tion. NADPH is necessary for driving synthetic mechanisms, and
it can be produced by isocitrate dehydrogenase 1 in the cytosol
and malic enzyme and isocitrate dehydrogenase 2 in mitochon-
dria (Cairns et al., 2011). When NADH is in excess, NADPH can
be formed from NADP+ in mitochondria by NADP+ transhydro-
genase and the energetics of the proton gradient (Jackson, 2003),
and compartmentation of the components of redox balance by
either subcellular organelles or protein chaperones may deserve
consideration (Arentson et al., 2012).
AMINO ACIDS IN PARAMETABOLIC REGULATION
The non-essential amino acids (NEAA) can play a special role in
parametabolic regulation. Of the 20 naturally occurring amino
acids, 11 are non-essential. The assignment was made purely
on a nutritional basis, i.e., the NEAA are not required in the
diet for optimal nutrition. Although some have inferred a less
important status for the NEAA, in actuality, the non-essentials pro-
vide critical non-proteinogenic functions. The enzymes for their
endogenous synthesis were evolutionarily preserved because they
contribute special regulatory functions in metabolism. Not sur-
prisingly, metabolism of the NEAA is important in cancer. The
role of glutamine has been emphasized (Dang, 2010), and recently
the pathway to serine and glycine is a detour from glycolysis; its
genomic and functional relevance to cancer has been recognized
(Locasale et al., 2011; Possemato et al., 2011). It is well known
that arginine and proline are interconvertible; the former is the
substrate for nitric oxide (Morris, 2009) and, through ornithine,
for polyamine synthesis. In contrast, proline, has not been studied
except by a few laboratories. Also worthy of mention, proline is
the only secondary proteinogenic amino acid (Adams and Frank,
1980). Because its alpha-amino group is contained within a pyrro-
lidine ring (see Figure 2), proline cannot be metabolized by the
usual amino acid enzymes, i.e., transaminases, decarboxylases,
racemases. Instead, a special family of enzymes has evolved and
these enzymes have their own regulatory mechanisms as well as
their own tissue and subcellular localization. These enzymes medi-
ate the interconversions of proline, glutamate, and arginine, but
as we shall see, their functions transcend their contributions to
supplying substrates for protein synthesis.
In the setting of interconvertibility of NEAA, the aforemen-
tioned pathways involving glutamate, proline, and arginine may
be summarized briefly here (see Figure 3). The central metabo-
lite is pyrroline-5-carboxylate (P5C) and its open-chain tautomer,
glutamic-γ -semialdehyde. These compounds, in tautomeric equi-
librium, are the obligate intermediates for transfer of carbons
between the TCA and urea cycles (Phang, 1985; Phang et al., 2001).
The fact that P5C is not only the precursor for proline synthesis
but also the immediate product of proline degradation aroused our
interest, because it is a feature unique in amino acid metabolism.
PROLINE METABOLISM AND REGULATION
The functional role of proline metabolism in redox regulation was
first recognized in the 1980s (Phang, 1985). Whether described
FIGURE 2 | Structure of molecules in the glutamine-arginine-proline
pathway. Glutamic-γ-semialdehyde is the open-chain tautomer of
∆1-pyrroline-5-carboxylic acid.
as a “proline cycle” or “redox shuttle” the interconversions of
proline and pyrroline-5-carboxylate, its oxidized congener, trans-
ferred redox equivalents between mitochondria and cytosol. The
enzymes catalyzing this cycle are proline oxidase (POX), also
known as proline dehydrogenase (PRODH) and pyrroline-5-
carboxylate reductase (PYCR). Using human erythrocytes which
have PYCR but no POX activity, we were able to demonstrate a
metabolic interlock (Yeh et al., 1984) with glucose-6-phosphate
dehydrogenase (G6PDH) of the PPP. The redox transfer robustly
activated the oxidative arm of the PPP and increased the forma-
tion of PP-Ribose-P, a critical intermediate for both salvage and
de novo pathways for nucleic acids (Yeh and Phang, 1981, 1983).
Interestingly, Wu described the flip side of this metabolic inter-
lock. Using porcine enterocytes, he showed that the oxidative arm
of the PPP is essential in the synthesis of proline from glutamine
(Wu, 1996).
PROLINE CYCLE REVISITED
Although the “proline cycle” as a redox regulatory system was
proposed almost three decades ago (Hagedorn and Phang, 1983;
Phang, 1985), its role in human metabolism was not understood
until a decade later (Polyak et al., 1997; Donald et al., 2001; Maxwell
and Rivera, 2003). Admittedly, its contributions to bioenergetics
and redox regulation were minor under conditions of oxygen and
substrate availability with optimal operation of the TCA cycle. Also
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FIGURE 3 | Enzymatic pathways in the interconversions of glutamine,
arginine, and proline. GSA (glutamic-γ-semialdehyde) and its tautomer,
P5C (∆1-pyrroline-5-carboxylate) bridge the pathways from glutamine to
arginine, thereby linking the TCA and urea cycles. Some reactions are
mediated by multiple isozymes with distinct subcellular localizations and
functions. The abbreviations are: PRO, proline; HYP, hydroxyproline; GLU,
glutamate; GLN, glutamine; a-KG, alphaketoglutarate; ORN, ornithine, CIT,
citrulline, ARG, arginine; NO, nitric oxide; PUT, putrescine; CP, carbamyl
phosphate. Enzymes catalyzing these reactions are designated by
numbers: 1, proline oxidase/dehydrogenase; 2, P5C reductase; 3, P5C
synthase; 4, P5C dehydrogenase; 5, glutaminase; 6, ornithine
aminotransferases; 7, ornithine transcarbamylase; 8, arginase; 9, ornithine
decarboxylase; 10, glutamate dehydrogenase; 11, protein synthesis; 12,
prolyl hydroxylase; 13, nitric oxide synthase.
widely accepted, the optimal functioning of antioxidant enzymes
and the glutathione cycle defends against redox toxicity. However,
with the recognition that redox signaling is a critical communica-
tion system, particularly under conditions of microenvironmental
stress, we formulated an overarching concept. A recent review (Cyr
and Domann, 2010) referred to our discoveries as the “Proline oxi-
dase (POX) Regulatory Axis” which we have shortened to “proline
regulatory axis” (PRA), a designation which includes the protean
regulatory effects of proline metabolism. Importantly, the discov-
ery that POX/PRODH is encoded by p53-induced gene 6 (PIG
6) provided persuasive evidence that the PRA provides meta-
bolic responses to stress situations (Polyak et al., 1997). Central
to this process is that POX/PRODH is bound to mitochondrial
inner membranes and donates electrons to the electron transport
chain (ETC; Donald et al., 2001; Liu et al., 2006, 2009; Phang et al.,
2008b).
REGULATION OF POX/PRODH
Not only is POX/PRODH regulated by p53, but also the apop-
totic response to p53 is dependent, in large part, on POX/PRODH
(Donald et al., 2001; Maxwell and Rivera, 2003; Liu et al., 2005;
Hu et al., 2007). In fact, the apoptotic response to p53 is decreased
∼60% when POX/PRODH is knocked down with siRNA (Maxwell
and Rivera, 2003). The mechanism of the POX/PRODH pro-
apoptotic effect is dependent on the generation of ROS (Don-
ald et al., 2001; Liu et al., 2005). Following this discovery that
POX/PRODH is a player in p53-induced apoptosis, we sought
to identify additional mechanisms by which POX/PRODH could
be induced (see Figure 4). Using a POX promoter/luciferase
construct as a target, we co-transfected a variety of transcrip-
tional factors. The usual transcriptional activators (jun/fos, NF-
kB) produced a modest effect in activating the POX/PRODH
promoter (less than twofold). Strikingly, the expression of per-
oxisome proliferator-activated receptor gamma (PPARγ robustly
activated the POX/PRODH promoter (Pandhare et al., 2006).
Furthermore, ligands of PPARγ, whether pharmacologic, e.g.,
Troglitazone, or physiologic, e.g., oxidized low-density lipoprotein,
induced POX/PRODH through a PPARγ-dependent mechanism
(Phang et al., 2008c; Zabirnyk et al., 2009). Our discovery that the
increase in POX/PRODH induced downstream targets through
a ROS-dependent signaling network was subsequently corrobo-
rated by several laboratories (Kim et al., 2007; Wang et al., 2011a).
Importantly, the apoptotic response to PPARγ and its ligands is
blocked by knocking down POX/PRODH. Thus, the regulated
activity of POX/PRODH plays a special role in the system for redox
signaling for apoptosis, and in other contexts, for autophagy and
survival (Phang et al., 2008c; Liu et al., 2012a).
To ascertain the response of the POX/PRODH response to
nutrient stress, we studied the effects of low glucose and/or
hypoxia (Pandhare et al., 2009; Liu et al., 2012a). We found that
POX/PRODH was upregulated by low glucose in a process medi-
ated by AMPK (Pandhare et al., 2009). Similarly, hypoxia increased
both HIF1 and AMPK signaling, but the effect on POX/PRODH
expression was attenuated by compound C, an inhibitor of AMPK
signaling but not by the knockdown of HIF1 (Liu et al., 2012a).
The POX/PRODH-mediated response in this context was activa-
tion of the pathway for autophagy and cell survival (Figure 4).
The response of POX/PRODH to hypoxia was translated to mice
with a tumor expressing GFP under the control of a hypoxia
response element (HRE). Both GFP and POX could be moni-
tored using immunohistochemistry. Strikingly, the expression of
HRE-controlled GFP and POX co-localized in various sections of
these xenograft tumors.
POX/PRODH PRODUCES ROS
Increasingly, it is recognized that mitochondria are the source
of intracellular ROS signaling. Although other enzymes can be
a source of superoxide (NADPH oxidase, xanthine oxidase), they
generally function for other purposes, e.g., as a bactericide, and in
general, this ROS is excreted extracellularly (Weinberg and Chan-
del, 2009). Although mitochondria are recognized as an important
if not unique source of ROS for signaling, the actual substrate
source and molecular mechanism remain uncertain. In general,
it has been thought that electrons donated to the ETC can be
mobilized for generating ROS. The work of Chandel and others
strongly suggested that Complex III is the source of ROS for sig-
naling (Chandel, 2010). They argue that the localization of this
complex allows the release of ROS into the intermembrane space
rather than into the mitochondrial matrix. Thus, such ROS may
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FIGURE 4 |Top: schematic representation of the functions of proline
oxidase (POX) in tumor suppression. POX functions as a tumor
suppressor even though the gene encoding POX is not a classical tumor
suppressor gene. Instead, POX is suppressed by a microRNA, miR-23b∗
which is over expressed in digestive tract and kidney cancers. For details,
see figure in review (Phang and Liu, 2012). Bottom: role of POX signaling
under conditions of metabolic stress. The functions of POX depend on
metabolic context. Under conditions of glucose or oxygen deprivation or
when treated with oxidized LDL, PPARγ, POX expression is upregulated.
The proline-dependent ROS generated by POX activate prosurvival
autophagy mediated by conversion of LC3 I to LC3 II and by expression
of Beclin.
be transferred to the cytosol which is the location of many targets
for such signaling. As mentioned above, POX/PRODH generates
proline-dependent ROS (Donald et al., 2001; Maxwell and Rivera,
2003; Liu et al., 2005; Kim et al., 2007; Wang et al., 2011a). Recently,
Chad Hancock in our laboratory has shown that electrons from
POX/PRODH are transferred from FAD to ubiquinone, as was first
shown by others in Saccharomyces (Wanduragala et al., 2010), and
then is transferred further to complex III for proline-dependent
ROS (Hancock, C., et al., in preparation; Liu et al., 2012b). Since
POX/PRODH can be robustly regulated in response to a variety of
stress mechanisms, it seems likely that this is a critical, regulated
pathway for the generation of ROS for signaling.
POX/PRODH FUNCTIONS AS A TUMOR SUPPRESSOR PROTEIN
The regulation of POX/PRODH and its generation of ROS for
signaling led us to study its effects on tumorigenesis in a mouse
model. Using DLD-tet-off-POX cells injected into immunodefi-
cient mice, the implantation, and growth of tumors was markedly
inhibited by the expression of POX/PRODH (Liu et al., 2009).
Additionally, using immunohistochemical methods to monitor
POX/PRODH levels in a variety of human tumors, we found that
POX/PRODH was much lower in tumors as compared to match-
ing normal tissues from the same patient, especially in tumors
of the digestive tract and kidney (Liu et al., 2009, 2010). These
findings suggested that POX/PRODH may function as a tumor
suppressor. However, gene sequencing identified no mutations in
the coding or promoter regions. Recently, the criterion for iden-
tification of tumor suppressive activity has expanded beyond the
classical definition of relying solely upon the mutated tumor sup-
pressor gene. For example, epigenetic mechanisms such as DNA
methylation and histone modification, as well as regulation of
gene expression by non-coding RNAs, have led to revised concepts
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of tumor suppressors. Additionally, metabolic enzymes have been
identified as mediators of tumor suppression (Thompson, 2009;
Luo et al., 2010). Due to these emerging concepts, our charac-
terization of POX/PRODH led us to propose that POX/PRODH
functions as a metabolic tumor suppressor protein (Liu et al., 2009;
Phang et al., 2010).
POX/PRODH IS REGULATED BY miR-23b∗
It was in the context of the above that we sought a mechanism for
the downregulation of POX expression in tumors. Wei Liu, in our
laboratory, discovered that a specific microRNA, miR-23b∗, was
increased in tumors compared to normal tissues. POX/PRODH
translation was suppressed by mimics of this microRNA, and
the POX/PRODH-mediated generation of ROS and induction of
apoptosis were inhibited by miR-23b∗ (Liu et al., 2010). Interest-
ingly, miR-23b, the sibling microRNA processed from the same
transcript as miR-23b∗, plays an important role in the regula-
tion of glutaminase, and miR-23 a/b is under the regulation of
MYC (Gao et al., 2009). In collaboration with Chi Dang and co-
workers at Johns Hopkins, we used the P493 cells, cells derived
from Burkitt’s lymphoma which carry a tet-off MYC expres-
sion vector and showed that MYC expression down regulated
POX/PRODH and suppressed both proline-dependent ROS pro-
duction and POX/PRODH-dependent apoptotic effects (Liu et al.,
2012b). Apparently, the suppression of POX/PRODH and its
growth-inhibitory and apoptotic effects exercised a permissive role
on the proliferative response to MYC.
∆1-PYRROLINE-5-CARBOXYLATE
Another feature of proline metabolism is provided by proline’s
oxidized congener,∆1-pyrroline-5-carboxylate (P5C). This mole-
cule is the product and substrate, respectively, of P5C synthase
and pyrroline-5-carboxylate reductase. The cyclized form is in
tautomeric equilibrium with its open-chain form, glutamic-γ-
semialdehyde (Adams, 1970). We can speculate that this inter-
convertibility can bestow special properties governed by the intra-
cellular milieu and allowing translocations and interactions not
available to other metabolites. We produced [U-14C]-l-pyrroline-
5-carboxylate enzymatically with [U-14C]-l-ornithine and par-
tially purified rat liver ornithine aminotransferases (Smith et al.,
1977). Using this radiolabeled [U-14C]-l-P5C, we showed that
the cellular transport of P5C had special properties (Mixson and
Phang, 1988, 1991). Although these were functionally defined over
20 years ago, they shed light on the functional interaction with
membranes. Not only was there an energy- and sodium-dependent
transport mechanism, but the uptake of P5C was distinct from
that for naturally occurring amino acids. Our studies suggested
that a transporter or channel existed in close association with P5C
reductase. In elegant studies by others, pyrroline-5-carboxylate
reductase was shown to exist in the native state as a decamer with
a “donut” like, torus structure common to membrane-associated
proteins and chaperones (Meng et al., 2006). Future studies will
define the structure of the other isozymes, PYCR2, and PYCRL (see
below).
We also developed an assay for P5C in biologic fluids using
PYCR purified from Escherichia coli (Fleming et al., 1984). With
this assay we were able to measure plasma levels and found that
it fluctuated with dietary intake (Fleming et al., 1989). Interest-
ingly, it was not related to proline intake. This is an area which
could be explored with state-of-the-art analytical methods in
metabolomics.
P5C REDUCTASES
Although two PYCRs have been functionally and molecularly rec-
ognized for some time (Dougherty et al., 1992; Hu et al., 2008;
Wu et al., 2008), a third PYCR (PYCRL or PYCR3) was identi-
fied (Suzuki et al., 2001). For mammalian cells, these have been
designated PYCR 1/2/L or by some workers, PYCR1/2/3. Recent
characterization of these three isozymes suggests that PYCR1
(Reversade et al., 2009) and PYCR2 are associated with mito-
chondria (De Ingeniis et al., under review); PYCR1 appears to be
transmembrane in mitochondria, and its torus structure may be
related to its transmembrane localization. PYCR2 is in the mito-
chondrial matrix whereas PYCRL is in the cytosol (De Ingeniis
et al., under review). The preferred reduced pyridine nucleotide
for PYCRL is NADPH whereas PYCR1/2 prefer NADH. As men-
tioned above, earlier work from our lab showed that PYCR activity
in human erythrocytes participates in a metabolic interlock with
G6PD and 6PGD of the PPP (Yeh et al., 1984). The increased pro-
duction of phosphoribosyl pyrophosphate was used for the salvage
pathway (Yeh and Phang, 1983). Subsequently, the PYCR from ery-
throcytes (most likely PYCRL) was purified to homogeneity. Not
only does the enzyme prefer NADPH, but the affinity for P5C
was higher with NADPH than with NADH (Merrill et al., 1989).
These and other findings led to the proposal that the erythrocyte
enzyme functioned as a P5C-dependent NADPH dehydrogenase.
The functional differences in PYCRs were recently reviewed (Hu
et al., 2008).
An inborn error with deficiency of PYCR1 has been described
associated with skeletal abnormalities, abnormal facial features,
and mental retardation (Reversade et al., 2009). Fibroblasts from
these patients have increased sensitivity to oxidative challenge.
Addition of hydrogen peroxide to normal fibroblasts would cause
no obvious damage whereas addition to the PYCR1-deficient
fibroblast caused cell death. These findings provide evidence in
a genetically derived inborn error that PYCR1 is associated with
redox regulation. However, with new data on the three PYCR
isozymes and their localizations, it becomes possible to propose
new metabolic interlocks from the “proline cycle” proposed over
25 years ago (Hagedorn and Phang, 1983; Phang, 1985). One
important feature of P5C reductases should be mentioned here.
As mentioned above, crystallographic characterization of PYCR1
shows it to be a decamer forming a torus (Meng et al., 2006).
Others have emphasized that such structures frequently are associ-
ated with membranes and also may function as a chaperone. One
could speculate that such a structure may form protein–protein
complexes to facilitate metabolic interlocks.
Since POX/PRODH is upregulated by p53, PPARγ, and AMPK
and functionally linked to apoptosis and autophagy, the early
proposal that the proline cycle allowed mitochondrial function
to be linked to proliferative responses needed revising. The all-
important consideration is context. For regulatory purposes,
POX/PRODH is generating ROS for signaling,and we have empha-
sized the importance of the PRA in apoptosis and autophagy,
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especially for ROS signaling from POX/PRODH. However, the
biosynthetic pathway linked to glutamine and MYC does not fit
into the aforementioned model. Instead, it may be best explained
by a parametabolic redox regulatory pathway.
Myc REGULATES GLUTAMINE AND PROLINE METABOLISM
Second in importance only to glucose in tumor metabolism, gluta-
mine is used as a source of bioenergetics as well as a donor of nitro-
gen for the biosynthesis of growth substrates, e.g., nucleotides.
Tracing glutamine metabolism with the use of [13C5, 15N2]-
glutamine by mass spectrometry and NMR, investigators showed
that as glutamate, the carbon skeleton from glutamine is converted
to alpha KG to serve an anaplerotic function for the TCA cycle, is
oxidized to CO2 and also is converted to lipids (Le et al., 2012). Of
special interest to us, in P493 cells expressing MYC controlled
by a tet-off promoter, a significant fraction of glutamine was
converted to proline. Importantly, suppression of MYC expres-
sion markedly decreased the conversion of glutamine to proline
(Liu et al., 2012b). It was shown previously that glutaminase, the
enzyme catalyzing the first step in glutamine metabolism, was
increased by MYC (Gao et al., 2009). With remarkable symme-
try, MYC not only downregulated POX/PRODH expression, but
markedly increased the enzymes converting glutamate to proline.
Both P5C synthase (P5CS) and pyrroline-5-carboxylate reduc-
tase 1 (PYCR1) protein levels were markedly increased (Liu et al.,
2012b). Importantly, monitoring the flux from labeled glutamine
showed that other than CO2, proline was a major end product
of glutamine in agreement with the findings of Windmueller and
Spaeth in the 1970s (Windmueller and Spaeth, 1974).
MYC IN ACTIVATED T-CELLS
Recently, Wang and co-workers, using a model of T-cell acti-
vation, reported that reprogramming of glutamine metabolism
played a crucial role, and MYC was the regulator which activated
glutamine metabolism (Wang et al., 2011b). Furthermore, they
showed that ALDH18A1 was markedly increased. The product
of this gene, pyrroline-5-carboylate synthase, plays a critical role
in intermediary metabolism synthesizing pyrroline-5-carboxylate
(or its open-chain tautomer, glutamic-γ-semialdehyde), the oblig-
ate intermediate in the transfer of carbons between the TCA
cycle and urea cycle. Activated T-cells showed increased levels
of ornithine and putrescine, and this was unaffected by knock-
out of arginase 1. Also, in studies using 13C-glutamine, these
workers found that MYC increased the routing of glutamine into
polyamines. In studies of splanchnic metabolism in the 1970s,
Windmueller and Spaeth (1974) showed that proline is a signif-
icant product of glutamine metabolism, but the current work
did not mention the routing of glutamine into proline. Wang
et al. emphasized the routing of glutamic-γ-semialdehyde/P5C
to polyamines, and they also showed that PRODH was upregu-
lated. The latter was in contrast to our finding where POX/PRODH
was down regulated with ectopic over expression of MYC in P493
Burkitt lymphoma cells (Liu et al., 2012b). In Wang’s model, nor-
mal T-cells were activated by immune stimulation in mice with
and without MYC knockout (Wang et al., 2011b). The disparities
in observed PRODH responses to MYC may be due to these con-
textual differences. Nevertheless, in both models, the emphasis is
on the upregulated synthesis of glutamic-γ-semialdehyde/P5C as
a central intermediate for MYC-activated proliferation.
PROLINE REGULATORY AXIS – A WORKING MODEL
In tumor cells, proliferation requires a steady supply of substrates
for cell mass. The two main sources are glucose and glutamine. As
others have pointed out, the metabolism of glucose through the
TCA cycle and oxidative phosphorylation, is an efficient generator
of ATP, and glycolysis is a rapid, albeit inefficient generator when
glucose is abundant. However, during tumor cell proliferation,
the carbons from glucose are required for producing nucleotides,
lipids, and other substrates for growth (Vander Heiden et al., 2009;
Cairns et al., 2011). Although pyruvate from glucose is an impor-
tant source of acetyl CoA for lipid biosynthesis, its conversion to
lactate is necessary for regeneration of NAD+ (Locasale and Cant-
ley, 2011). Similarly, the critical step for nucleotide synthesis by
both de novo and salvage pathways is the oxidative arm of the PPP.
Although there are alternative pathways for ribose production, i.e.,
through the non-oxidative arm of the PPP, rapidly proliferating
cells may use either pathway depending on the metabolic context,
especially when glucose is readily available (Miccheli et al., 2006;
Tong et al., 2009). The critical factor for maintaining ribose for-
mation through the oxidative arm is the availability of NADP+ for
the first two steps catalyzed by glucose-6-phosphate dehydroge-
nase and 6-phosphogluconate dehydrogenase, respectively (Veech
et al., 1969). Thus, we see that two important steps in channeling
glucose carbons into cell mass, require the recycling of NAD+ and
NADP+ for glycolysis and the oxidative arm of the PPP, respec-
tively. The PRA not only provides p53-induced proline-dependent
ROS signaling for metabolic stress, but also the regeneration of
oxidizing potential for channeling glucose and glutamine carbons
into cell mass for proliferation.
MYC AND PARAMETABOLIC REGULATION
In P493 cells bearing a tet-off MYC construct, MYC induced both
P5C synthase and PYCR1. Consistent with these findings, the flux
of (U-13C5, 15N2)-glutamine to proline is increased nearly 10-fold
with the expression of MYC (Liu et al., 2012b). These findings sug-
gested that the pathway to proline activated a process transcending
the proteinogenic function of proline. In fact, in most growing
cells, concomitant with the consumption of glutamine, proline is
produced in excess of growth requirements and is secreted into
the medium (Stoner and Merchant, 1972). The reason for this
marked MYC-dependent increase in the flux of glutamine to pro-
line is not fully understood. We are in the process of showing
that MYC expression greatly increased glycolysis as well as oxida-
tive phosphorylation, and with knockdown of P5CS or PYCR1,
the stimulatory effect of MYC was markedly inhibited (Liu, W.,
et al., unpublished observations). Additionally, from work done
in the 1970s, the exposure of cells to organically synthesized dl-
pyrroline-5-carboxylic acid resulted in a large increase in the flux
of glucose through the PPP (Phang et al., 1982). This metabolic
interlock was thought to be due to the P5C-mediated oxidation of
NADPH by P5C reductase (Merrill et al., 1989) and was further
substantiated by reconstituted cell-free experiments (Hagedorn
and Phang, 1983; Phang, 1985). A number of studies have shown
that MYC is associated with increased activity of the oxidative arm
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of the PPP (Palaskas et al., 2011; Wang et al., 2011b; Manganelli
et al., 2012). Our working hypothesis is that the MYC activation
of PYCR may be the metabolic link to the activation of the PPP by
MYC. From the recent work on isozymes of P5C reductase, a rea-
sonable assumption would be that this was mediated by PYCRL,
the isozyme which prefers NADPH as co-factor (De Ingeniis et al.,
under review). These findings suggest that although glutamine is
the source of carbons taken up by the cell, it is the conversion of
glutamate to P5C and subsequently to proline which is providing
the necessary parametabolic regulation to optimize glucose utiliza-
tion for cell proliferation. Not only do these findings add to the
important functions of glutamine, but suggest that the glutamine-
proline pathway is also critical, and it could be targeted selectively
for cancer therapy.
These recent developments and new experimental findings
indicated that the “Proline cycle” is one component of a more
comprehensive “PRA.” With redundant PYCRs, we can hypothe-
size a number of cycles which can be activated by specific signals
for metabolic reprogramming. The data supporting the classi-
cal “proline cycle” was from studies using reconstituted cellu-
lar components, and the interpretation was that it served as an
auxiliary energy-producing mechanism linking the complete oxi-
dation of glucose in the PPP to oxidative phosphorylation with
the proline cycle as the shuttle mechanism. We now know that
the generation of ROS for signaling is an important function
of POX/PRODH, a signaling mechanism responsive to a vari-
ety of factors (p53, PPARγ, AMPK). The recent discovery that
MYC activates the biosynthetic arm of proline metabolism sug-
gests several novel hypothetical arrangements. First, the marked
upregulation of P5CS increases the production of P5C from glu-
tamate. P5C has a number of fates: it can be cycled back to
glutamate, it can be converted to ornithine by ornithine amino-
transferases or it can be converted to proline by one of the three
isozymes of P5C reductase (see Figure 5). Based on their respec-
tive subcellular localizations and characteristics, we can speculate
that PYCR1 can regenerate NAD+ in the cytosol whereas PYCR2
regenerates NAD+ in the mitochondrial matrix. PYCRL, however,
generates NADP+ in the cytosol. One would expect that if these
three PYCRs have metabolic interlocks with glucose metabolism,
PYCR1/2 would be linked with glycolysis whereas PYCRL would
be linked with the PPP. Thus, the biosynthetic arm of the PRA can
provide parametabolic redox regulation for glucose metabolism
and MYC induction of both P5CS and PYCR may be necessary
components of reprogramming by MYC to direct glucose into
cell mass.
GLUTAMINE TO PROLINE PATHWAY MEDIATES REDOX REGULATION
As mentioned above, a number of reviews have emphasized the
role of lactate excretion as a mechanism for regenerating oxidizing
potential in the form of NAD+ to maintain increased glucose flux
into necessary substrates for cell mass (Cairns et al., 2011; Locasale
and Cantley, 2011). Additionally, although the PPP has been pri-
marily considered as a glucose-dependent source of reducing
potential to defend against oxidative stress, during reprogramming
of cells for growth with the mandatory increase of nucleotides, the
oxidative arm of the PPP is activated. Such was the case during acti-
vation of T-cells. The flux through the oxidative arm of the PPP
is dependent on the level of G6PD and 6PGD, but only in part;
FIGURE 5 | A proposed model for parametabolic redox regulation by the
proline regulatory axis.The model is a composite of functions which depend
on temporo-spatial context; various activities may not occur simultaneously.
For example, MYC inhibits POX but concomitantly activates P5CS and PYCR1
(see text). The enzymes shown are as follows: GLS, glutaminase; GS,
glutamine synthase; P5CS, pyrroline-5-carboxylate synthase, P5CDH,
pyrroline-5-carboxylate dehydrogenase; POX, proline oxidase/dehydrogenase;
PYCR1/2, pyrroline-5-carboxylate reductase 1, and 2; PYCRL,
pyrroline-5-carboxylate reductase L. Some of the pathways are simplified. A
single arrow may represent multiple steps.
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it is also regulated by NADP/NADPH ratios (Veech et al., 1969).
This is because NADPH is the competitive inhibitor of NADP+ in
its binding to G6PD. For most resting cells, NADPH is predomi-
nant and there is little flux through the oxidative arm. However, as
NADPH is oxidized, the flux through the PPP markedly increases.
Thus, for both glycolysis and for the oxidative arm of the PPP,
redox regulation is critical.
Depending on which P5C reductase isozyme is used to catalyze
the reaction, the pathway from glutamate to proline would oxidize
two molecules of NAD(P)+. The fact that there is this metabolic
interlock at the PYCR step with the PPP has been shown in a
variety of reconstituted systems (Phang et al., 1980; Hagedorn
and Phang, 1986). Our ongoing studies using the Seahorse XF
flux analyzer has shown that the extracellular acidification rate
(ECAR), which may be considered an indicator of lactate for-
mation, is increased with MYC expression, and this effect can be
markedly inhibited with the knockdown of either P5CS or PYCR1.
Thus, the glutamine to proline pathway is serving as a parameta-
bolic regulator of redox to optimize flux from glucose to substrates
for cell mass.
THE FATE OF PROLINE
But what happens to the proline? As mentioned above, endoge-
nously synthesized proline can be secreted from the cell (Stoner
and Merchant, 1972), or it can be incorporated into collagen
(Priest and Davies, 1969) as a sink for proline. When collagen
is synthesized, 25% of the amino acids incorporated are pro-
line (Udenfriend, 1966; Phang et al., 2001). Subsequently, about
half of these proline residues are hydroxylated forming hydrox-
yproline. From the perspective of redox balance, collagen can be
a sink for reducing potential and be removed from the meta-
bolic pool, but it’s removal from the microenvironment, unlike
lactate, is unnecessary. In fact, in many sites with cellular hyper-
proliferation, collagen synthesis is increased. For example, breast
carcinogenesis is often accompanied by collagen formation (Priest
and Davies, 1969). A dense, collagen-rich mass co-localizes with
the proliferation of tumor cells (Kao et al., 1986; Alowami et al.,
2003; Li et al., 2005; Schedin and Keely, 2011), even if the actual
production of collagen takes place in stromal cells rather than
in tumor cells. Cross-regulation between collagen synthesis and
tumor cell proliferation may be mediated by mechanoregulatory
(Provenzano et al., 2008) or metabolic reprogramming mecha-
nisms (Walker and Shand, 1972; Savolainen et al., 1984; Anthony
et al., 2010). The latter suggestion is plausible because metabolic
abnormalities concomitant to inflammatory proliferation is fre-
quently associated with collagen formation, i.e., fibrosis (Davis
and Cowie, 1990; Eddy and Giachelli, 1995). This occurs in the
lung with chronic infection or autoimmune activation (Verma
and Slutsky, 2007).
Collagen requires both proline and hydroxyproline (see
Figure 2), but free hydroxyproline is not incorporated into
proteins (Stetten, 1949). Instead, proline is post-translationally
hydroxylated (Peterkofsky and Udenfriend, 1965). But, there are
parallels in proline versus hydroxyproline metabolism (Cooper
et al., 2008). Importantly, there are distinct oxidases (dehy-
drogenases) for the respective imino acids (Adams and Frank,
1980), with little substrate overlap, and hydroyproline oxidase,
like proline oxidase, is induced by p53, and can generate ROS
(Cooper et al., 2008). However, the respective second step in the
degradation, pyrroline-5-carboxyalte dehydrogenase and 3-OH-
pyrroline-5-carboxylate dehydrogenase are catalyzed by the same
enzyme (Valle et al., 1979; Flynn et al., 1989). Humans with an
inherited defect in this enzyme accumulate 3-OH-P5C as well
as P5C in blood and excrete large amounts of the two pyrro-
line carboxylates in the urine. Interestingly, P5C reductase, or at
least PYCR1, can use either P5C or 3-OH-P5C as substrate, but
this property is not found in enzymes from prokaryotes (Adams,
1970; Steinberg, 1973). Thus, both of these compounds can be
used to recycle NAD(P)+. In the 1970s when a number of work-
ers were monitoring the regulation of collagen synthesis, several
described a rather interesting phenomenon. As much as 40% of
the nascent hydroxylated collagen is not secreted from the cell
(Steinberg, 1973). Instead it is degraded to release free hydrox-
yproline. This apparent wastage of bioenergy could be due to a
metabolic function for hydroxyproline and its metabolites which
have not yet been identified. Nevertheless, the metabolic pathways
for hydroxyproline can act as a backup for those for proline in
the PRA.
CONCLUSION
In recent years, the reprogramming of non-essential amino
acid metabolism has attracted attention. We now introduce the
concept of “parametabolic regulation” to help understand this
reprogramming. Simply stated, it is not the amino acids which
are the important products. Rather, their synthesis and degra-
dation provide the scaffold for regenerating or cycling sub-
strates necessary for optimal function of core pathways. The
PRA provides a model for such a parametabolic regulatory
system.
Since the original formulation of the regulatory functions of
proline and its oxidized congener,∆1-pyrroline-5-carboxylate, the
understanding of the physiologic and pathophysiologic functions
of the PRA has undergone considerable change. We have been
like “blind men and the elephant.” However, the insights provided
by a number of laboratories have helped us interpret the new
findings.
The interconversions of proline, arginine and glutamate are
important under various nutritionally stressed situations, i.e., the
production of arginine from proline may augment growth when
dietary arginine is deficient, e.g., in weanling pigs (Wu et al.,
2008). Additionally, the production of alpha KG from glutamate
derived from either proline or arginine may have an anaplerotic
role for the TCA cycle. However, there are important linkages
with redox which may be the principal regulatory function of
the PRA. POX/PRODH is a regulated source of ROS for signal-
ing. The ROS signaling role, described by our laboratory, has
been corroborated by other labs. P5C, whether produced from
arginine via ornithine, from glutamate by P5CS or from proline
by POX/PRODH is a carrier or transfer mechanism for pyridine
nucleotide-dependent oxidizing potential. The PRA also plays a
role in the reprogramming of cellular metabolism by MYC. This
transduction mechanism has been shown to be dependent on
P5C reductase and its three isozymes with specific subcellular
localizations and individual preferences for NADPH or NADH.
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Depending on the regulation of this pathway by specific oncogenes,
the reprogramming of metabolism may be dependent on the para-
metabolic regulation provided by the PRA. We are examining the
regulation of the specific enzymes by mechanisms from genomic,
epigenetic, and non-coding RNA origins. We will verify the meta-
bolic interlocks with important pathways, i.e., glycolysis, PPP,
Serine-glycine pathway. The uncovering of these parametabolic
mechanisms and the specific reprogramming in various tumors
may lead us to the ultimate goal of identifying novel targets for
cancer therapy.
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